MBRX

Moleculin Biotec

• TipRanks·15h ago

  Moleculin Highlights Annamycin Cardiac Safety Data at ASCO

• PUBT·1d ago

  Moleculin says ASCO accepts pooled cardiac safety analysis for Annamycin poster

• Benzinga·05/15 13:20

  Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate

• Reuters·05/15 12:44

  Moleculin Biotech Q1 net loss widens as R&D costs rise

• Seeking Alpha·05/15 12:34

  Moleculin Biotech GAAP EPS of -$3.54 misses by $2.08

• PUBT·05/15 12:32

  Moleculin reports 40% blinded remission rate in pivotal MIRACLE AML trial

• Dow Jones·05/15 12:31

  *Moleculin Biotech: Runway to Support Planned Operations Into 3Q 2026 >MBRX

• Reuters·05/15 12:30

  MOLECULIN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE ON PIVOTAL MIRACLE TRIAL

• Dow Jones·05/15 12:30

  *Moleculin Biotech 1Q Loss/Shr $3.54 >MBRX

• TipRanks·05/15 10:26

  Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress and Safety Profile Support Unchanged $22 Price Target

• PUBT·05/14 20:02

  Moleculin Biotech Q1 FY26 net loss widens to $12.85 million; operating loss widens to $7.87 million

• TipRanks·05/14 19:25

  Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target

• Benzinga·05/13 16:41

  Nano-Cap Moleculin Biotech Approaches Key Leukemia Trial Data Unblinding

• TipRanks·05/13 14:09

  Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30

• TipRanks·05/13 12:33

  Moleculin Nears First Unblinding in Pivotal MIRACLE Trial